前瞻性临床试验推进免疫检查点抑制剂毒性研究。
Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity.
机构信息
Beaumont Hospital, RCSI Cancer Centre, D09 V2N0 Dublin, Ireland.
Department of Medicine, RCSI University of Medicine and Health Sciences, D02 YN77 Dublin, Ireland.
出版信息
Curr Oncol. 2023 Jul 20;30(7):6862-6871. doi: 10.3390/curroncol30070502.
Abstract
Immune checkpoint inhibitors (ICIs) are a class of drug that produces durable and sustained anti-tumour responses in a wide variety of malignancies. The exponential rise in their use has been mirrored by a rise in immune-related adverse events (IrAEs). Knowledge of such toxicities, as well as effective management algorithms for these toxicities, is essential to optimize clinical efficacy and safety. Currently, the guidelines for management of the IrAEs are based largely on retrospective studies and case series. In this article, we review the current landscape of clinical trials investigating the management of IrAEs with an aim to develop standardised, randomised controlled trial-based management algorithms for ICI-related toxicities.
摘要
免疫检查点抑制剂（ICIs）是一类药物，可在多种恶性肿瘤中产生持久和持续的抗肿瘤反应。随着其应用的迅速增加，免疫相关不良事件（IrAEs）也随之增加。了解这些毒性以及针对这些毒性的有效管理算法对于优化临床疗效和安全性至关重要。目前，IrAEs 管理指南主要基于回顾性研究和病例系列。在本文中，我们回顾了目前正在进行的临床试验，以研究 IrAEs 的管理，旨在为 ICI 相关毒性制定标准化、基于随机对照试验的管理算法。
相似文献
1
Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity.前瞻性临床试验推进免疫检查点抑制剂毒性研究。
Curr Oncol. 2023 Jul 20;30(7):6862-6871. doi: 10.3390/curroncol30070502.
2
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.与免疫检查点抑制剂相关的极重度免疫相关不良事件的决定因素：法国 REISAMIC 注册前瞻性研究。
Eur J Cancer. 2021 Nov;158:217-224. doi: 10.1016/j.ejca.2021.08.048. Epub 2021 Oct 7.
3
[Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies].[恶性肿瘤中检查点抑制剂诱导的免疫相关不良事件的预测生物标志物]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2020 Dec 30;42(6):825-830. doi: 10.3881/j.issn.1000-503X.11534.
4
Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.肠道微生物组和微生物衍生代谢物在免疫相关不良事件中的意义：癌症免疫治疗新型生物标志物的出现。
Int J Mol Sci. 2023 Feb 1;24(3):2769. doi: 10.3390/ijms24032769.
5
Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.美国 FDA 批准的免疫检查点抑制剂的毒性负担模式。
J Exp Clin Cancer Res. 2023 Jan 5;42(1):4. doi: 10.1186/s13046-022-02568-y.
6
Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer.肺癌免疫检查点抑制剂的 3 期临床试验免疫相关不良事件的荟萃分析。
Crit Rev Oncol Hematol. 2021 Jun;162:103351. doi: 10.1016/j.critrevonc.2021.103351. Epub 2021 May 12.
7
Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors.综述文章：免疫检查点抑制剂的胃肠道、胰腺和肝脏毒性的当代管理。
Aliment Pharmacol Ther. 2024 Jun;59(11):1350-1365. doi: 10.1111/apt.17980. Epub 2024 Apr 8.
8
Controversies on the possible role of immune checkpoint inhibitors in pediatric cancers: balancing irAEs and efficacy.免疫检查点抑制剂在儿科癌症中可能作用的争议：平衡 irAEs 和疗效。
Tumori. 2021 Aug;107(4):276-281. doi: 10.1177/03008916211010214. Epub 2021 Apr 20.
9
Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.免疫相关不良事件和免疫检查点抑制剂再挑战中的耐受：单中心经验。
J Cancer Res Clin Oncol. 2021 Sep;147(9):2789-2800. doi: 10.1007/s00432-021-03610-w. Epub 2021 Mar 28.
10
Management of immune checkpoint inhibitor-related dermatologic adverse events.免疫检查点抑制剂相关皮肤不良反应的管理。
Thorac Cancer. 2020 Feb;11(2):488-492. doi: 10.1111/1759-7714.13275. Epub 2019 Dec 9.
引用本文的文献
1
Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma.阿替利珠单抗和贝伐单抗治疗不可切除肝细胞癌的拉丁美洲多中心队列中的免疫介导不良事件
Oncotarget. 2025 May 19;16:348-360. doi: 10.18632/oncotarget.28721.
2
Immunotherapy-induced psoriasis successfully treated with Guselkumab in a patient with metastatic gastric cancer.在一名转移性胃癌患者中，古塞库单抗成功治疗免疫疗法诱发的银屑病。
An Bras Dermatol. 2025 May-Jun;100(3):590-593. doi: 10.1016/j.abd.2024.08.009. Epub 2025 Mar 13.
3
Determinants of immune checkpoint inhibitor use and factors linked to neurological adverse events in Korean lung cancer.韩国肺癌患者免疫检查点抑制剂使用的决定因素及与神经不良事件相关的因素
Future Oncol. 2024 Dec;20(39):3245-3256. doi: 10.1080/14796694.2024.2416378. Epub 2024 Oct 25.
4
Acknowledging and addressing real-world challenges to treating immune-related adverse events.承认和解决治疗免疫相关不良反应的现实挑战。
J Immunother Cancer. 2024 Jul 22;12(7):e009540. doi: 10.1136/jitc-2024-009540.
5
Clinical and translational attributes of immune-related adverse events.免疫相关不良反应的临床和转化特征。
Nat Cancer. 2024 Apr;5(4):557-571. doi: 10.1038/s43018-024-00730-3. Epub 2024 Feb 15.
本文引用的文献
1
Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis.阿巴西普/芦可替尼联合筛查伴发呼吸肌无力以降低免疫检查点抑制剂心肌炎的致死率。
Cancer Discov. 2023 May 4;13(5):1100-1115. doi: 10.1158/2159-8290.CD-22-1180.
2
Intentional treatment with tofacitinib in a patient with severe refractory ulcerative colitis and concomitant Sars-CoV-2 infection.对一名患有严重难治性溃疡性结肠炎并伴有新型冠状病毒2型（SARS-CoV-2）感染的患者进行托法替布的意向性治疗。
Dig Liver Dis. 2022 Nov;54(11):1598-1599. doi: 10.1016/j.dld.2022.08.038. Epub 2022 Sep 6.
3
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.托法替布治疗溃疡性结肠炎：全球临床项目长达 7.8 年的安全性汇总数据综合摘要。
J Crohns Colitis. 2023 Apr 3;17(3):338-351. doi: 10.1093/ecco-jcc/jjac141.
4
Review article: guide to tofacitinib dosing in patients with ulcerative colitis.综述文章：溃疡性结肠炎患者托法替布剂量指南。
Aliment Pharmacol Ther. 2022 Oct;56(7):1131-1145. doi: 10.1111/apt.17185. Epub 2022 Aug 22.
5
Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective.托法替尼治疗溃疡性结肠炎的定位：全球视角。
Expert Rev Gastroenterol Hepatol. 2022 Aug;16(8):737-752. doi: 10.1080/17474124.2022.2106216. Epub 2022 Aug 2.
6
Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer.免疫相关不良反应的风险因素和预测因素：对非小细胞肺癌患者的意义。
Expert Rev Anticancer Ther. 2022 Aug;22(8):861-874. doi: 10.1080/14737140.2022.2094772. Epub 2022 Jul 4.
7
Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.免疫相关不良事件的风险因素和生物标志物：识别高风险患者及重新使用免疫检查点抑制剂的实用指南
Front Immunol. 2022 Apr 26;13:779691. doi: 10.3389/fimmu.2022.779691. eCollection 2022.
8
Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management.免疫检查点抑制剂相关的眼部不良事件：对其机制、诊断和管理的当前认识
Int J Ophthalmol. 2022 Apr 18;15(4):646-656. doi: 10.18240/ijo.2022.04.19. eCollection 2022.
9
Immune-related adverse events and the balancing act of immunotherapy.免疫相关不良反应与免疫治疗的平衡艺术。
Nat Commun. 2022 Jan 19;13(1):392. doi: 10.1038/s41467-022-27960-2.
10
Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management.免疫检查点抑制剂与肾脏毒性：诊断与管理进展
Kidney Med. 2021 Oct 8;3(6):1074-1081. doi: 10.1016/j.xkme.2021.08.008. eCollection 2021 Nov-Dec.
Zotero 插件